Archivel Farma S.L. is a biotechnology company that specializes in the development of innovative immunotherapeutic products, particularly focusing on the RUTI® vaccine aimed at treating tuberculosis (TB). The company operates under Good Manufacturing Practices (GMP) and has established a Biosafety Level 3 (BSL-3) facility, which is essential for handling pathogens like Mycobacterium tuberculosis. Archivel Farma's manufacturing capabilities include the production of injectable and freeze-dried biological products, with a focus on small customized clinical batches. The RUTI® vaccine is designed to enhance the efficacy of standard antibiotic treatments for TB, particularly in cases of multidrug-resistant TB, by boosting the immune response and potentially shortening the duration of therapy.

In addition to its core focus on tuberculosis, Archivel Farma is exploring the use of the RUTI® vaccine for other medical indications, such as bladder cancer. The vaccine is formulated as a liposome suspension containing cell wall nanofragments of Mycobacterium tuberculosis, which helps to stimulate a robust immune response. The company is actively engaged in clinical trials to assess the vaccine's effectiveness and safety, with ongoing studies in various countries. Archivel Farma's commitment to research and development, along with its advanced manufacturing capabilities, positions it as a key player in the fight against TB and other related diseases.

Spain

Archivel Farma is a biotech R&D company focused on the development of innovative immunotherapeutic products, notably in sterile, injectable and lyophilised products.
Archivel Farma is currently developing, as its own project, RUTI®, a therapeutic vaccine for the treatment of active tuberculosis. 

Archivel Farma S.L.

Company Details